Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLI1100 in moderate-severe facial acne vulgaris
NCT02604680Phase 2Completed
- Sponsor
- Braintree Laboratories
- Start
- Oct 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BLI1100 in acne vulgaris (5 arms), sponsored by Braintree Laboratories. Primary endpoints: Absolute change in total lesion count at 12 weeks and Treatment success based on Investigator Global Assessment at 12 weeks. Started Oct 2015; status: completed.
02
Drugs
BLI1100
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02604680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02604680.